Introduction
============

Osteoarthritis is a chronic degenerative disorder that causes pain, stiffness, and limited range of motion in affected joints.[@b1-jpr-9-847] Causes of osteoarthritis include cartilage degradation, subchondral bone outgrowths, synovial hypertrophy, and altered ligament integrity.[@b2-jpr-9-847] Injection therapies are most commonly administered when pain or functional limitations of osteoarthritis are significant despite oral medication or exercise.[@b3-jpr-9-847] While injection of corticosteroids is the most common regimen for musculoskeletal disorders, it merely provides short-term improvement of symptoms while posing the risk of aggravating cartilage damage and producing tissue atrophy.[@b4-jpr-9-847] Administration of hyaluronic acid is another common approach to replenishing dysfunctional synovial fluid in joints affected by osteoarthritis. However, according to the results of a recent large-scale meta-analysis, this approach offers only a clinically irrelevant benefit.[@b5-jpr-9-847]

Regenerative therapy involves the injection of a small volume of solution into multiple sites of painful ligament and tendon insertions (entheses) and adjacent joint spaces, with the goal of reducing pain and ostensibly promoting tissue repair and growth.[@b6-jpr-9-847] Hyperosmolar dextrose, the most commonly used solution, was first examined in the treatment of osteoarthritis in randomized controlled trials (RCTs) in 2000.[@b7-jpr-9-847],[@b8-jpr-9-847] The proposed mechanism by which dextrose prolotherapy alleviates joint degenerative disorders includes creating a hyperosmolar environment to induce cell rupture and release platelet-derived growth factor.[@b9-jpr-9-847] In recent years, increasing evidence has supported the use of dextrose prolotherapy for patients with osteoarthritis.[@b10-jpr-9-847] However, the magnitude of benefit of prolotherapy may be affected by variations in treatment protocols, evaluation intervals, and therapeutic measurement tools. Therefore, we designed a meta-analysis to evaluate the effect of using dextrose prolotherapy in the treatment of osteoarthritis.

Methods
=======

Two electronic databases, PubMed and Scopus, were explored from their earliest records until February 2016.[@b11-jpr-9-847]--[@b15-jpr-9-847] The Cochrane Collaboration Central Register of Controlled Clinical Trials, Cochrane Systematic Reviews ([ClinicalTrials.gov](http://ClinicalTrials.gov)), which includes bibliographies of included trials and related systematic reviews, was also checked for pertinent references. The key terms encompassed prolotherapy, dextrose, cartilage, degeneration, and osteoarthritis, and were entered as medical subject headings and text words for searches.

We included single-arm prospective studies, studies with non-randomized assignment to control or active treatment (quasi-experimental studies), and RCTs. Case series lacking a predestinated therapeutic protocol and a follow-up plan were excluded. The inclusion criteria for studies and RCTs were as follows: (1) they should involve adult participants with degenerative cartilage disorders, regardless of the affected sites; (2) they should involve adults receiving serial dextrose injections to the involved joints in at least one treatment arm of a study; and (3) they should be studies providing quantitative measurement of functional change or pain reduction before and after interventions.

Data extraction and quality assessment
--------------------------------------

Two authors (C-YH and M-YH) independently assessed all the relevant literature and extracted the following data from selected studies: patient demographics, dosage and inter val of dextrose administrations, injection techniques, and changes in functional outcome measurements. The quality of the RCTs was appraised by the Jadad scale, the composite scores of which ranged from 0 to 5 points. Studies that scored fewer than 3 points were regarded to have poorly designed methodology.[@b12-jpr-9-847]--[@b14-jpr-9-847] The Newcastle--Ottawa Scale, which has a maximal score of 9 points, was used to evaluate the quality of selection, comparability, exposure, and outcome in single-arm and quasi-experimental studies.[@b12-jpr-9-847]--[@b14-jpr-9-847] A total score less than 4 points was assumed to signify a study that was low in quality. Discrepancies in opinions between the two evaluators were resolved by discussion or a ruling by the corresponding author.

Data synthesis and analysis
---------------------------

The main outcome was determined by the severity of pain, derived from the visual analog scale or knee pain scale. The first priority of pain measurement extraction was the pain score during movement/walking because of a stronger association with patient's function. If pain score with movement/walking was not available in the trial, we used the pain subscale from Western Ontario and McMaster Universities Arthritis Index as the substitute. To assess the effectiveness of dextrose prolotherapy compared with the baseline condition, we used the standardized mean difference between the baseline and status after treatment in the treatment arm using dextrose prolotherapy. Data were calculated from the ratio of the difference between baseline and posttreatment pain to the standard deviation (SD) of pooled results, (Pain~baseline~ − Pain~posttreatment~)/pooled SD. Pooled SD equaled the square root of {\[(participant numbers in baseline − 1)\*(standard deviation of pain scales in baseline)[@b2-jpr-9-847] − (participant numbers after treatment − 1)\*(standard deviation of pain scales after treatment)[@b2-jpr-9-847]\]/\[(participant numbers in baseline -- 1) − (participant numbers after treatment -- 1)\]}.[@b12-jpr-9-847],[@b13-jpr-9-847] A positive value of the effect size indicated a decrease in pain compared with baseline.

In terms of the effect size of dextrose prolotherapy compared with other injection treatments, we used the ratio of the difference in reduction of pain between the dextrose and reference groups to the pooled SD, (Pain reduction~dextrose~ -- Pain reduction~reference~)/pooled SD. Pooled SD was generated from the square root of {\[(participant numbers in the dextrose group − 1)\*(standard deviation of pain reduction in the dextrose group)[@b2-jpr-9-847] − (participant numbers in the control group -- 1)\*(standard deviation of changes in pain in the control group)[@b2-jpr-9-847]\]/\[(participant numbers in the dextrose group − 1) − (participant numbers in the control group − 1)\[}.[@b12-jpr-9-847],[@b13-jpr-9-847] A positive value of the effect size indicated a favorable result after dextrose prolotherapy.

The random effect model was used to pool the effect sizes, and the heterogeneity was determined by *I*-square and Cochran's *Q* methods.[@b16-jpr-9-847] Whether the effect sizes were modified by the involved joints and difference in control groups was assessed by the subgroup analysis. The funnel plot and Egger test were used to examine the publication bias, defined as the tendency for positive trials to be published and the tendency for negative and null trials not to be published.[@b17-jpr-9-847] All analyses were performed using Stata 10.0 (StataCorp LP, College Station, TX, USA), and *p* \< 0.05 was considered statistically significant.

Results
=======

Study search and patient characteristics
----------------------------------------

Of the 170 non-duplicate citations identified from the literature, eleven studies were screened for eligibility ([Figure 1](#f1-jpr-9-847){ref-type="fig"}). We excluded one single-arm trial, due to lack of quantitative pain evaluation in patients with patellar chondro-arthropathy,[@b18-jpr-9-847] one RCT comparing single injection of dextrose with erythropoietin,[@b19-jpr-9-847] one RCT targeting nonspecific chronic low back pain without definite radiologic evidence of lumbar spine osteoarthritis,[@b20-jpr-9-847] and two observational studies analyzing data from a published RCT exploring knee osteoarthritis.[@b21-jpr-9-847],[@b22-jpr-9-847] The final meta-analysis included one single-arm follow-up trial[@b23-jpr-9-847] and five RCTs,[@b7-jpr-9-847],[@b8-jpr-9-847],[@b24-jpr-9-847]--[@b26-jpr-9-847] four of which probed knee osteoarthri tis[@b7-jpr-9-847],[@b23-jpr-9-847],[@b24-jpr-9-847],[@b26-jpr-9-847] and two of which examined hand osteoarthritis.[@b8-jpr-9-847],[@b25-jpr-9-847] Regarding the comparative injection regimens in the five RCTs, one used two serial saline injections followed by one shot of corticosteroids,[@b25-jpr-9-847] three used sequential administrations of local anesthetics,[@b7-jpr-9-847],[@b8-jpr-9-847],[@b24-jpr-9-847] and one used a crossover design by implementing the dextrose injection at different time points.[@b26-jpr-9-847]

The meta-analysis enrolled a total of 326 participants, 190 (58.3%) of whom were females. Ages ranged from 56.4 to 64.5 years. The duration from the onset of symptoms to being registered in the study was from 10.7 to 108.0 months. The diagnosis of osteoarthritis was verified by radiographic findings in each trial. As regards the quality assessment, all the RCTs obtained a maximal 2 points in the aspect of "randomization" in Jadad scale since appropriate randomization methods were mentioned. In the aspect of "blinding", all the RCTs had appropriate blinding methods (maximal 2 points) except the study by Dumais et al[@b26-jpr-9-847] which did not mention a blinded design of intervention and evaluation (earning 0 points). In the aspect of "an account of all patients", the two studies conducted by Reeves and Hassanein,[@b7-jpr-9-847],[@b8-jpr-9-847] the one by Rabago et al,[@b24-jpr-9-847] and the one by Dumais et al[@b26-jpr-9-847] had descriptions of the outcome of all the patients at the end of the studies (earning 1 point). The results of the quality assessment are listed in [Table 1](#t1-jpr-9-847){ref-type="table"}. The preparations and injection details of each retrieved study are summarized in [Table 2](#t2-jpr-9-847){ref-type="table"}.

Pooled effect sizes
-------------------

Regarding the treatment arm using dextrose prolotherapy, the effect sizes compared with baseline were 0.65 (95% confidence interval \[CI\], 0.14--1.17), 0.84 (95% CI, 0.40--1.27), 0.85 (95% CI, 0.60--1.10), and 0.87 (95% CI, 0.53--1.21) after the first, second, third, and fourth or more injections, respectively ([Figure 2](#f2-jpr-9-847){ref-type="fig"}). In terms of the comparisons between dextrose prolotherapy and other injected solutions, we extracted the data closest to the sixth month after the first injection, which was the last follow-up point available in most studies. The effect size of dextrose prolotherapy compared with other injected solutions was 0.36 (95% CI, 0.10--0.63) ([Figure 3A](#f3-jpr-9-847){ref-type="fig"}), while that compared with exercise was 0.71 (95% CI, 0.30--1.11) ([Figure 3B](#f3-jpr-9-847){ref-type="fig"}).

The subgroup analysis showed that dextrose prolotherapy had a superior effect to local anesthesia (effect size, 0.38; 95% CI, 0.07--0.70) and an insignificant advantage over corticosteroids (effect size, 0.31; 95% CI, −0.18 to 0.80) ([Figure 3C](#f3-jpr-9-847){ref-type="fig"}). There was no difference in the effect sizes regarding the use of dextrose prolotherapy compared with control injection between knee and hand joints ([Figure 3D](#f3-jpr-9-847){ref-type="fig"}). No publication bias (*p*=0.8, determined by the Begg's test) and funnel plot asymmetry were detected in terms of the effect size comparing dextrose prolotherapy and other injected solutions.

Discussion
==========

Our meta-analysis included one single-arm study and five RCTs, and found that dextrose injection reduced pain in patients with hand and knee osteoarthritis compared with their pretreated baseline levels. However, we did not identify a positive dose--response relationship following serial dextrose injections. Dextrose prolotherapy was more effective than local anesthetics injection and exercise, and had an insignificant advantage over corticosteroids. The subgroup analysis further showed that the effect of prolotherapy did not differ between hand and knee osteoarthritis.

Dextrose prolotherapy has been used for treating musculoskeletal pain for decades, but the number of clinical trials investigating its effectiveness is still limited. In 2005, a systematic review summarized case reports, case series, and clinical trials using prolotherapy in the treatment of chronic musculoskeletal pain and found a potential benefit of prolotherapy on osteoarthritis but an inconsistent outcome on low back pain.[@b27-jpr-9-847] In 2011, a narrative review investigated the same issue, disclosing a favorable trend of prolotherapy in treating osteoarthritis and chronic tendinopathy.[@b6-jpr-9-847] In 2016, Sit et al conducted a meta-analysis regarding the use of dextrose in the treatment of symptomatic osteoarthritis, mentioning a potential positive effect of prolotherapy. However, their analysis did not include patients with hand osteoarthritis.[@b28-jpr-9-847] Since 2013, three more RCTs have been published regarding the use of dextrose injection for hand and knee osteoarthritis.[@b19-jpr-9-847],[@b24-jpr-9-847],[@b25-jpr-9-847] Two of these studies showed a superior effect of dextrose administration over the reference regimen. The inconsistency might have arisen from heterogeneity in enrolled participants, differences in injection techniques, and volumes and selections of injected joints. Therefore, a quantitative analysis was required to examine the dose--response relationship and true effect of dextrose prolotherapy in the treatment of osteoarthritis.

We selectively analyzed the serial changes between the baseline and posttreatment status within the dextrose group. The purpose was to examine whether additional injections could reduce more pain or sustain the duration of symptomatic relief. We were aware that the effect size derived from the comparison with the pretreatment condition was overestimated due to the placebo effect and could not be used as true effectiveness of a treatment and was only used as a surrogate approach for evaluation of a potential dose--response relationship ([Figure 2](#f2-jpr-9-847){ref-type="fig"}).

In our study, the effect of dextrose prolotherapy was positive compared with the reference regimen and exercise at 6 months following the first injection. The result from the comparison between dextrose and exercise was within expectations because injection and needling carry a strong placebo effect, which usually leads to superior response to the noninvasive treatment. The values of the effect size indicated moderately superior treatment effect of dextrose to local anesthetics and corticosteroids.[@b29-jpr-9-847] Corticosteroids was known to provide short-term pain relief for osteoarthritic knees in a previous meta-analysis,[@b4-jpr-9-847] and the effect did not last for more than 3 months after administration. In our subgroup analysis, dextrose showed an insignificant benefit over corticosteroids. The reason for lacking statistical significance might be attributed to insufficient study numbers (only one trial) using corticosteroids as reference. Our data implied that dextrose prolotherapy was potentially more effective than an anti-inflammatory (corticosteroids) regimen or placebo (local anesthetics). Furthermore, although the injection volumes of dextrose for small joints differed remarkably from those for large joints, the subgroup analysis did not reveal a significant difference between hand and knee osteoarthritis.

Study limitations
-----------------

Our study had several limitations. First, the number of trials eligible for meta-analysis was limited, and heterogeneity existed in the patient populations, injection protocols, comparative regimens, and outcome assessment. Second, we did not analyze effect sizes of functional improvements because the data were not available in each retrieved trial. Third, although previous research proposed that the benefit of dextrose prolotherapy derived from its chondo-protective effect or modulation of intra-articular cytokines, these theories could not be proved by our meta-analysis since there were few data about the measurement of cartilage thickness and intra-articular cytokine level in the retrieved articles. Fourth, hyaluronic acid and platelet-rich plasma are known to counteract osteoarthritis.[@b13-jpr-9-847],[@b30-jpr-9-847] Although dextrose prolotherapy appeared to be more effective than the use of corticosteroids and local anesthetics, the comparison with commonly used regimens like hyaluronic acid or platelet-rich plasma was lacking in our literature search. This subject should be investigated in future prospective studies. Fifth, the treatment responsiveness using binary data, which considered the standard outcome variable in pain medicine, is not reported in the included studies. Therefore, we used the effect sizes retrieved from continuous variables like changes in pain or function instead in the quantitative analysis. Finally, the interpretation of the effect of dextrose compared with corticosteroids should be cautious because the finding was derived from only a single study.

Conclusion
==========

Compared with pretreatment baseline, dextrose injections decreased pain in osteoarthritis patients but did not exhibit a positive dose--response relationship following serial injections. Dextrose prolotherapy was found to provide a better therapeutic effect than exercise, local anesthetics, and probably corticosteroids when patients were retested 6 months following the initial injection. The effect of prolotherapy did not differ between hand and knee osteoarthritis
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![Flow diagram of the evaluation process for the inclusion or exclusion of studies. Adapted from Moher et al.[@b31-jpr-9-847]\
**Abbreviation:** RCT, randomized controlled trial.](jpr-9-847Fig1){#f1-jpr-9-847}

![Forest plot of the effect of pain reduction from baseline after the first, second, third, and fourth or more injections.\
**Abbreviations:** ES, effect size; CI, confidence interval.](jpr-9-847Fig2){#f2-jpr-9-847}

![Forest plot of comparisons of the effect size between dextrose prolotherapy and the reference treatments: (**A**) the pooled result from four randomized controlled trials comparing dextrose with other injections; (**B**) the pooled result comparing dextrose and exercise; and (**C**) the subgroup analysis based on different comparative injectates and (**D**) the affected joints.\
**Abbreviations:** ES, effect size; CI, confidence interval; OA, osteoarthritis.](jpr-9-847Fig3){#f3-jpr-9-847}

###### 

Summary of studies that investigated the therapeutic effect of dextrose prolotherapy on patients with osteoarthritis

  Study                                 Disease                                                                                                 Enrolled sample number                                                                                                                                                                  Average age                                                                       Symptom duration                                                                           Severity of OA on radiographs                                                                                                                             Double- blind   Intention-to-treat   Outcome measure(s)                                                                                                                                                                                                                   Follow-up timing                       Adverse event                                                                                                                  Quality assessment
  ------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------
  **Randomized control trial**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Reeves and Hassanein[@b8-jpr-9-847]   Thumb and finger OA (distal interphalangeal, proximal interphalangeal, and trapeziometacarpal joints)   Dextrose: 13 (5 M, 8 F); control: 14 (6 M, 8 F)                                                                                                                                         Dextrose: 64.5 ± 9.2 years; control: 63.9 ± 9.4 years                             Dextrose: 59 ± 117 months; placebo: 50 ± 42.2 months                                       Moderate osteophytosis, moderate joint space narrowing, or mild osteophytosis plus mild joint space narrowing                                             Yes             Yes                  VAS for pain at rest, with joint movement and with grip; joint flexion range in degrees                                                                                                                                              6 and 12 months                        One patient with a flare of pain at the thumb at the 12th month follow-up                                                      5[a](#tfn1-jpr-9-847){ref-type="table-fn"}
  Reeves and Hassanein[@b7-jpr-9-847]   Knee OA                                                                                                 Overall 77 patients in the dextrose and control groups; 58% males                                                                                                                       63 years for all knee OA participants                                             6 months or more                                                                           Either grade 2 or more joint narrowing or grade 2 or more osteophytic change                                                                              Yes             Not mentioned        VAS for pain and swelling, frequency of leg buckling, goniometrically measured flexion, radiographic measures of joint narrowing and osteophytosis, and KT1000- measured anterior displacement difference                            6 and 12 months                        One patient with a postinjection flare                                                                                         5[a](#tfn1-jpr-9-847){ref-type="table-fn"}
  Dumais et al[@b26-jpr-9-847]          Knee OA                                                                                                 Group A (dextrose on weeks 0, 4, 8, and 12 in combination with exercise): 18 (11 M, 7 F); group B (dextrose on weeks 20, 24, 28, and 32 in combination with exercise): 18 (8 M, 10 F)   Group A: 57.3 ± 12.6 years; group B: 56.2 ± 10.9 years                            6 months or more                                                                           Kellgren--Lawrence score: group A: grade I: 2, II: 1, III: 10, IV: 5; group B: grade I: 1, II: 1, III: 11, IV: 5                                          No              Not mentioned        WOMAC, pain intensity, and functional impairment from Brief Pain Inventory, Wong-Baker Faces Pain Rating Scale, simple descriptive intensity scale, numeric distress scale, VAS, and combined pain score of all the aforementioned   Every 4 weeks in a 36-week period      One patient with diffuse edema of both legs at weeks 24 and 28                                                                 3[a](#tfn1-jpr-9-847){ref-type="table-fn"}
  Rabago et al[@b24-jpr-9-847]          Knee OA                                                                                                 Dextrose: 30 (11 M, 19 F); control: 29 (9 M, 20 F); exercise: 31 (10 M, 21 F)                                                                                                           Dextrose: 56.8 ± 7.9 years; control: 56.8 ± 6.7 years; exercise: 56.4 ± 7 years   Dextrose: 79.8 ± 62.9 months; control: 108.0 ± 99.5 months; exercise: 60.4 ± 71.6 months   Kellgren--Lawrence score: dextrose: grade I--II: 11, III--IV: 14; control: I--II: 12, III--IV: 9; exercise: grade I--II: 9, III--IV: 14                   Yes             Not mentioned        WOMAC, KPS, procedure-related pain severity, and patient satisfaction                                                                                                                                                                Baseline, 5, 9, 12, 26, and 52 weeks   All patients with mild-to-moderate postinjection pain; 3 in dextrose group and 5 in saline group with self-limiting bruising   5[a](#tfn1-jpr-9-847){ref-type="table-fn"}
  Jahangiri et al[@b25-jpr-9-847]       First carpometacarpal joint OA                                                                          Dextrose: 30 (7 M, 23 F); control: 30 (9 M, 21 F)                                                                                                                                       Dextrose: 63.9 ± 9.4 years; control: 63.3 ± 10.1 years                            Dextrose: 10.7 ± 7.7 months; control: 11.3 ± 9.3 months                                    Moderate osteophytosis, moderate joint space narrowing, or mild osteophytosis plus mild joint space narrowing, or subchondral sclerosis, or subluxation   Yes             Not mentioned        VAS, HAQ-DI                                                                                                                                                                                                                          Baseline, 1, 2, and 6 months           Three patients with transient increases in pain at the site of injection                                                       4[a](#tfn1-jpr-9-847){ref-type="table-fn"}
  **Single-arm prospective study**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Rabago et al[@b23-jpr-9-847]          Knee OA                                                                                                 36 (15 M, 21 F)                                                                                                                                                                         60 ± 8.7 years                                                                    81.2 ± 72.9 months                                                                         Kellgren--Lawrence score: grade I--II: 8, grade III--IV: 23                                                                                               NA              Not mentioned        WOMAC, KPS, procedure-related pain severity, and patient satisfaction                                                                                                                                                                Baseline, 5, 9, 12, 26, and 52 weeks   No                                                                                                                             4[b](#tfn2-jpr-9-847){ref-type="table-fn"}

**Notes:**

Quality scores derived from the Jadad scale.

Quality scores derived from the Newcastle--Ottawa Scale.

**Abbreviations:** OA, osteoarthritis; M, male; F, female; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index; KPS, knee pain scale; HAQ-DI, Health Assessment Questionnaire Disability Index; NA, not applicable.

###### 

Summary of the preparations and injection details of prolotherapy in the retrieved trials

  Study                                 Total number of injection doses                                                      Volume per dose                                                                                  Interval of injection   Regimen                                                                                                                                                                                                       Comparison                                                                                                                                                                                                                                                                                                                                                Injection technique                                                                                                                                                                                                                                Pain measurement extracted for analysis
  ------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  **Randomized controlled trial**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Reeves and Hassanein[@b8-jpr-9-847]   3 (3 basic doses but additional injections were allowed in the open-label period)    0.25--0.5 mL at each injection site                                                              2 months                10% dextrose and 0.075% lidocaine in bacteriostatic water                                                                                                                                                     0.075% lidocaine in bacteriostatic water                                                                                                                                                                                                                                                                                                                  A 27-gauge needle was inserted at the joint line of all symptomatic DIP, PIP, and thumb CMC joints laterally and medially until firm resistance was felt                                                                                           Pain during walking
  Reeves and Hassanein[@b7-jpr-9-847]   3 (3 basic doses but additional injections were allowed at 6, 8, and 10 months)      9 mL                                                                                             2 months                10% dextrose and 0.075% lidocaine in bacteriostatic water                                                                                                                                                     0.075% lidocaine in bacteriostatic water                                                                                                                                                                                                                                                                                                                  A 27-gauge needle through an inferomedial approach to inject the tibiofemoral joint                                                                                                                                                                Pain during movement
  Dumais et al[@b26-jpr-9-847]          4                                                                                    Intra-articular: 5 mL; extra-articular: 1 mL at each of 8 sites in the collateral ligaments      4 weeks                 Intra-articular: 20% dextrose and 0.5% lidocaine; extra-articular: 15% dextrose and 0.6% lidocaine                                                                                                            One group receiving injections on weeks 0, 4, 8, and 12; the other group receiving injections on weeks 20, 24, 28, and 32. Both receiving 32 weeks of exercise (isometric quadriceps exercises, leg extension exercises with quadriceps roll, straight leg raise, and sitting end-range knee extension), 10 repetitions daily                             Intra-articular: anterior approach; extra-articular: the osteotendinous junction of both insertion sites of the collateral ligaments was identified                                                                                                Pain subscale from WOMAC
  Rabago et al[@b24-jpr-9-847]          3 (3 basic doses with 2 additional injections if the physicians thought necessary)   Intra-articular: 6 mL; extra-articular: 0.5 mL at each ligament--bone insertion, up to 22.5 mL   4 weeks                 Intra-articular: 25% dextrose (5 mL of 50% dextrose mixed with 5 mL of 1% lidocaine); extra-articular: 15% dextrose (6.75 mL of 50% dextrose mixed with 4.5 mL of 1% lidocaine and 11.25 mL of 0.9% saline)   Control: intra-articular: 5 mL of 0.9% saline with 5 mL of 1% lidocaine; extra-articular: 18 mL of 0.9% saline with 4.5 mL of 1% lidocaine. Exercise: 10 at-home knee exercises, begin with 3 sessions per week, 1 session daily, 10 repetitions per exercise; increase as tolerated to 5 sessions per week, 3 times daily, 15 repetitions per exercise   Intra-articular injection through an inferomedial approach; extra-articular injection: up to 15 subdermal injections and 0.5 mL of 15% solution was injected using a peppering technique with a 25-guage needle at each ligament-bone injection    Pain subscale from WOMAC
  Jahangiri et al[@b25-jpr-9-847]       3                                                                                    1 mL                                                                                             1 month                 0.5 mL of 20% dextrose mixed with 0.5 mL of 2% lidocaine                                                                                                                                                      2 monthly placebo injections of 1 mL of 0.9 % saline, followed by a single dose of 40 mg methylprednisolone acetate (0.5 mL) mixed with 0.5 mL of 2% lidocaine in the 3rd month                                                                                                                                                                           A 25-gauge needle was inserted toward the ulnar side of the extensor pollicis brevis and just proximal to the base of the first metacarpal in the snuffbox                                                                                         Pain during movement
  **Single-arm prospective study**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Rabago et al[@b23-jpr-9-847]          3 (3 basic doses with 2 additional injections if the physicians thought necessary)   Intra-articular: 6 mL; extra-articular: 0.5 mL at each ligament--bone insertion, up to 22.5 mL   4 weeks                 Intra-articular: 25% dextrose (5 mL of 50% dextrose, 5 mL of 1% lidocaine); extra-articular: 15% dextrose (6.75 mL of 50% dextrose mixed with 4.5 mL of 1% lidocaine and 11.25 mL of 0.9% saline)             NA                                                                                                                                                                                                                                                                                                                                                        Intra-articular injection through an inferomedial approach; extra-articular injection: up to 15 subdermal injections and 0.5 mL of 15% solution was injected using a peppering technique with a 25-guage needle at each ligament--bone injection   Pain subscale from WOMAC

**Abbreviations:** DIP, distal interphalangeal; PIP, proximal interphalangeal; CMC, carpometacarpal; WOMAC, Western Ontario and McMaster Universities Arthritis Index; NA, not applicable.
